99 related articles for article (PubMed ID: 11432894)
21. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Prados MD; Lamborn K; Yung WK; Jaeckle K; Robins HI; Mehta M; Fine HA; Wen PY; Cloughesy T; Chang S; Nicholas MK; Schiff D; Greenberg H; Junck L; Fink K; Hess K; Kuhn J;
Neuro Oncol; 2006 Apr; 8(2):189-93. PubMed ID: 16533878
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E; Jakacki R; Goldman S; Hargrave D; Hawkins C; Shroff M; Hukin J; Bartels U; Foreman N; Kellie S; Hilden J; Etzl M; Wilson B; Stephens D; Tabori U; Baruchel S
J Clin Oncol; 2012 Apr; 30(12):1358-63. PubMed ID: 22393086
[TBL] [Abstract][Full Text] [Related]
24. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
Schwer AL; Damek DM; Kavanagh BD; Gaspar LE; Lillehei K; Stuhr K; Chen C
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):993-1001. PubMed ID: 17967517
[TBL] [Abstract][Full Text] [Related]
25. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Franceschi E; Cavallo G; Lonardi S; Magrini E; Tosoni A; Grosso D; Scopece L; Blatt V; Urbini B; Pession A; Tallini G; Crinò L; Brandes AA
Br J Cancer; 2007 Apr; 96(7):1047-51. PubMed ID: 17353924
[TBL] [Abstract][Full Text] [Related]
26. Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Friedman HS; Petros WP; Friedman AH; Schaaf LJ; Kerby T; Lawyer J; Parry M; Houghton PJ; Lovell S; Rasheed K; Cloughsey T; Stewart ES; Colvin OM; Provenzale JM; McLendon RE; Bigner DD; Cokgor I; Haglund M; Rich J; Ashley D; Malczyn J; Elfring GL; Miller LL
J Clin Oncol; 1999 May; 17(5):1516-25. PubMed ID: 10334539
[TBL] [Abstract][Full Text] [Related]
27. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Jaeckle KA; Hess KR; Yung WK; Greenberg H; Fine H; Schiff D; Pollack IF; Kuhn J; Fink K; Mehta M; Cloughesy T; Nicholas MK; Chang S; Prados M;
J Clin Oncol; 2003 Jun; 21(12):2305-11. PubMed ID: 12805331
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
Hassler MR; Ackerl M; Flechl B; Sax C; Wöhrer A; Widhalm G; Dieckmann K; Hainfellner J; Preusser M; Marosi C
Anticancer Drugs; 2014 Jul; 25(6):723-8. PubMed ID: 24441743
[TBL] [Abstract][Full Text] [Related]
31. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
Yung WK; Kyritsis AP; Gleason MJ; Levin VA
Clin Cancer Res; 1996 Dec; 2(12):1931-5. PubMed ID: 9816151
[TBL] [Abstract][Full Text] [Related]
32. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
Raymond E; Brandes AA; Dittrich C; Fumoleau P; Coudert B; Clement PM; Frenay M; Rampling R; Stupp R; Kros JM; Heinrich MC; Gorlia T; Lacombe D; van den Bent MJ;
J Clin Oncol; 2008 Oct; 26(28):4659-65. PubMed ID: 18824712
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.
Gounder MM; Nayak L; Sahebjam S; Muzikansky A; Sanchez AJ; Desideri S; Ye X; Ivy SP; Nabors LB; Prados M; Grossman S; DeAngelis LM; Wen PY
J Clin Oncol; 2015 Oct; 33(28):3186-92. PubMed ID: 26282642
[TBL] [Abstract][Full Text] [Related]
35. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Kocher M; Kunze S; Eich HT; Semrau R; Müller RP
Strahlenther Onkol; 2005 Mar; 181(3):157-63. PubMed ID: 15756519
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
[TBL] [Abstract][Full Text] [Related]
39. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Salloum R; Hummel TR; Kumar SS; Dorris K; Li S; Lin T; Daryani VM; Stewart CF; Miles L; Poussaint TY; Stevenson C; Goldman S; Dhall G; Packer R; Fisher P; Pollack IF; Fouladi M; Boyett J; Drissi R
J Neurooncol; 2016 Sep; 129(3):443-451. PubMed ID: 27350411
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]